View More Recent Stories

Jan 13, 2016 06:31PM Lancet Oncology Publishes Results from the Phase 2 TERRAIN Trial of enzalutamide Compared to bicalutamide in Metastatic Castration-Resistant Prostate Cancer
Jan 13, 2016 02:37PM Astellas Agrees to PGA TOUR Sponsorship through 2020
Dec 6, 2015 04:30PM Astellas Announces Updated Data from the Phase 1/2 CHRYSALIS Trial for Gilteritinib (ASP2215) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Nov 30, 2015 04:05PM Astellas and Ironwood Report Positive Top-Line Data from Phase III IBS-C Trial Conducted in Japan
Nov 17, 2015 10:20AM Astellas Announces New Data to be Presented at the 2015 ASH Annual Meeting
Jun 4, 2015 12:00PM Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award
Jun 1, 2015 05:00PM New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting
May 30, 2015 03:07PM Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML)
May 17, 2015 12:52PM Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
May 14, 2015 07:00AM Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting
May 5, 2015 07:00AM Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
Apr 21, 2015 07:30PM Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics
View More Recent Stories